1 / 9

Pharming Overview

Pharming Overview. May 2006.

miette
Télécharger la présentation

Pharming Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharming Overview May 2006 This presentation contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. Powered by Bioscience, Focused on Products

  2. Overview • Based in Leiden, Netherlands and USA • Euronext listing;1989 - 2001 ‘Research Era’ • Production of recombinant proteins for restoration and repair • Role of protein cascades (Complement, Clotting) • 2002 - 2005 ‘Turnaround & Refocus’ • 240 40 60 employees • Lead product rhC1INH being filed for HAE • Clinical work on major new indications • rhLactoferrin filed for GRAS indication in USA • rhFibrinogen and rhCollagen development • Novel protein manufacturing system validated History Technology Organisation Products

  3. Strategic Evolution Survival Focus Innovation Collaboration • Financing • Research • Organisation • rhC1 INH • rh LF • Cash Flow • Restructuring • Compassionate Use • Manufacturing • Marketing • Diosynth • Paul Capital • Novathera • DNage 2001A 2002A 2004A 2005A 2006 - 07 Equity€ (1) M € 11 M € 36 M € 29 M € 50 M + Debt € (24) M € (5) M Near Zero Near Zero Near Zero Annual Loss€ (54) M € (1) M € (14) M € (18) M ZCB Employees 250 40 48 60 60+ Products 1 1 4 4+ 6+ Mkt Cap€ 4 M € 16 M € 150 M € 325 M

  4. Product Pipeline Accelerate Product Flow to the Market Status Product Application Market Size rhC1INH rhFibrinogen rhFib Sealant rhLactoferrin rhCollagen Novathera Combos Technology > € 500 million > € 1 billion > € 1 billion € 100 million > € 1 billion > € 1 billion > € 1 billion > € 1 billion Phase III Filing in first market In the clinic Intermediate Device Food (GRAS) Device Intermediate Device Under Development Licensing • HAE • New Indications • Intermediate • Control bleeding • Nutraceutical • Anti-infective • Intermediate • Cosmetic / Other • Tissue Repair • Catheters, Stents • Protein Production

  5. Protein ProductionTechnology Select protein Generate genetic constructs Develop founder/ mini-herd Expand herd Purify protein from milk Formulate Protein therapeutic

  6. HAE - Patient Centric Approach A congenital deficiency of functional C1 inhibitor (C1INH) characterised by recurrent localised angioedema due to uncontrolled activation of complement and contact systems 22,000 patients, 160,000 attacks per year relationship with patient organizations facilitating patient care Patient Register share information with regulatory authorities relationships with key opinion leaders

  7. Rec. Human C1 inhibitor Phase III for HAE • Rapid relief • (usually 15 minutes) • Complete resolution • (12 - 24 hours) • No ADRs reported • Report published • April 2005

  8. Rec. Human LactoferrinFiled with US FDA for GRAS • For functional and • sport foods • Doses of upto 2g/kg in • toxicity studies • Safe for oral use • Report published • Jan 2006

  9. Future Outlook 2006 – 08Capitalize on solid financial position • Strong news flow from filings, partnerships and launches for rhC1INH and rhLF • Partnerships for Pharming technology platforms and product pipeline • Generate sustainable revenues via rhC1INH and rhLF launches • Establish critical mass to build a biotechnology company with world class R&D and commercial capabilities

More Related